Dermatology

Moderator Greg Bensch and a panel of allergists discuss itch control, access barriers, and guideline gaps shaping newer AD topicals in this clinical forum.

How should clinicians choose atopic dermatitis treatments? Harrison Nguyen, MD, discusses personalized therapy and when to escalate care.

In this episode of The Medical Sisterhood, physician entrepreneurship is explored as Meagen McCusker, MD, shares lessons on private practice, leadership, and career.

How is drug selection evolving in atopic dermatitis? Walter Liszewski, MD, discusses personalized therapy and long-term care.

Walter Liszewski, MD, discusses how dermatologists can personalize atopic dermatitis treatment using biologics, JAK inhibitors, and topicals.

Jason Hawkes, MD, explains how new biologics and targeted therapies are advancing precision medicine and improving personalized care in atopic dermatitis.

GLP-1 receptor agonists show early promise for psoriasis and HS, but 3 experts urge caution on mechanism, durability, and long-term safety.

Jason Hawkes, MD, highlights issues related to prior authorization as well as raising awareness of chronic urticaria, HS, atopic dermatitis, and other diseases.

Experts unpack where new eczema creams fit, and why insurance hurdles and steroid fear keep patients from faster itch relief.

Most newer nonsteroidal topical options are now approved for children as young as 2 years. Linda Stein Gold, MD, discusses adherence and misconceptions of pediatric AD.

New topical mechanisms introduce more ways to control pediatric AD without the sting, burn, or long-term steroid concerns that limit adherence, Linda Stein Gold, MD, says.

Stay updated with the latest healthcare breakthroughs, including FDA approvals, phase 3 data, and open-label extension results.

Erythema was less frequent with combination therapy than with phototherapy alone, according to Giovanni Leone, MD.

In this discussion during UV Safety Awareness Month, Suozzi highlights tips on reversing photodamage and sun protection misconceptions.

5 dermatology takeaways from Maui Derm NP+PA Summer 2026, covering eczematous dermatitis, rosacea, blistering disease, hair loss, and pigmentation disorders.

Hosts discuss the latest data in psoriasis and the case for treating scalp, nail, and genital psoriasis as systemic-eligible disease.

In this SDPA interview, Matthew Zirwas, MD, highlights key takeaways from his session 'Clinical Pearls for Optimizing Dermatologic Care.'

In this SDPA Conference interview, Zirwas continues his discussion of increasing environmental impacts on rates of atopic dermatitis.

Matthew Zirwas, MD, speaks in this SDPA interview about evidence for atopic dermatitis being more of an environmental disease than a genetic one.

Combination therapy outperformed excimer light alone for vitiligo, according to Giovanni Leone, MD.

Bempikibart use led to clinically meaningful SALT improvements among those with alopecia areata in the phase 2a SIGNAL-AA study at 36 weeks.

In this podcast episode, 2 featured experts discuss AI, teledermatology, and strategies to reduce bias in skin of color dermatologic care.

As July is UV Safety Awareness Month, key tips for addressing sun damage, skin cancer signs, photoaging, and more are highlighted in this discussion.

Martin discussed where hydroquinone still fits, why oral tranexamic acid remains underused, and how he decides when to escalate to procedural therapy.

In this Q&A interview, Davinder Parsad, MD, highlights vitiligo misconceptions and upcoming news in the vitiligo treatment pipeline.